The three most expensive words in the pharmaceutical world may well be "one more trial", but "Soiree in Monaco" doesn't sound cheap either. I wonder which has the better potential IRR for shareholders.
- Forums
- ASX - By Stock
- CUV
- Ann: Appendix 4E and Annual Report to Shareholders 2023
Ann: Appendix 4E and Annual Report to Shareholders 2023, page-20
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.58 |
Change
0.000(0.00%) |
Mkt cap ! $730.1M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 57 | $15.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.86 | 206 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 57 | 15.140 |
4 | 83 | 15.090 |
1 | 500 | 15.000 |
2 | 1537 | 14.700 |
1 | 362 | 14.660 |
Price($) | Vol. | No. |
---|---|---|
13.860 | 206 | 4 |
14.300 | 50 | 1 |
14.590 | 125 | 2 |
14.600 | 90 | 1 |
14.610 | 90 | 1 |
Last trade - 09.37am 10/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online